Silence Therapeutics (SLN) Current Deferred Revenue (2019 - 2025)
Silence Therapeutics (SLN) posted Current Deferred Revenue of $168000.0 for Q4 2025, down 44.19% sequentially from $301000.0 in Q3 2025, and down 45.1% YoY from $306000.0 in Q4 2024.
Silence Therapeutics (SLN) Current Deferred Revenue (2019 - 2025) Analysis & Trends
Silence Therapeutics has reported Current Deferred Revenue for 7 years, with the latest figure at $168000.0 in Q4 2025.
- Quarterly Current Deferred Revenue fell 45.1% year-over-year to $168000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $168000.0 (down 45.1% YoY) and the FY2025 annual result came in at $168000.0, down 45.1% from the prior year.
- Current Deferred Revenue slipped to $168000.0 in Q4 2025 per SLN's latest filing, from $301000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $10.4 million in Q4 2022 and troughed at $168000.0 in Q4 2025.
- A 5-year average of $3.0 million and a median of $424500.0 in 2025 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue jumped 81.6% in 2022, then sank 95.22% in 2024.
- Over 5 years, Current Deferred Revenue stood at $5.7 million in 2021, then surged by 81.6% to $10.4 million in 2022, then slumped by 38.39% to $6.4 million in 2023, then slumped by 95.22% to $306000.0 in 2024, then plunged by 45.1% to $168000.0 in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $168000.0, $301000.0, and $457000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 168,000.00 |
| Sep 30, 2025 | 301,000.00 |
| Jun 30, 2025 | 457,000.00 |
| Mar 31, 2025 | 392,000.00 |
| Dec 31, 2024 | 306,000.00 |
| Dec 31, 2023 | 6.41 Mn |
| Dec 31, 2022 | 10.40 Mn |
| Dec 31, 2021 | 5.73 Mn |
| Dec 31, 2020 | 22.50 Mn |
| Dec 31, 2019 | 3.19 Mn |